- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07805590
Virus-virus Interactions Among Patients Admitted to the Hospices Civils de Lyon, During 2022 to 2025 Winters Seasons (INTERVI)
Respiratory viruses circulate throughout the year, and particularly during the winter. Consequently, co-infections involving two or more viruses can occur. The study of virus-virus interactions at the population level is necessary to understand the dynamics of co-infections. Viruses such as IAV (influenza A virus) and rhinoviruses (common cold viruses) are known to have a negative interaction, mutually excluding one another, which results in a reduced likelihood of co-infection. The study of virus-virus interactions at the population level constitutes an essential first step towards understanding and characterising these phenomena at the individual level, and subsequently at the cellular level. Using integrative approaches combining epidemiological data, clinical observations and in vitro models, it has been shown that IAV and SARS-CoV-2 have a negative interaction, whilst potentially contributing to the severity of respiratory infections. This research also suggests that prior vaccination against IAV reduces the risk of severe forms of the disease.
Furthermore, viral co-infections appear to influence the severity of respiratory infections, particularly in children. Children appear to be more susceptible to these co-infections, with around 35% of cases reported, compared with 6% in adults. In this context, the study and characterisation of virus-virus interactions appear essential to better understand the pathophysiology of respiratory infections and improve the management of co-infected patients.
Every week, Dr Jean-Sébastien Casalegno publishes the Hospices Civils' epidemiological bulletin, which considers the prevalence of respiratory viruses detected at the Centre de Biologie et Pathologie Nord. This local dataset reports on the co-circulation of respiratory viruses and is of interest for the study of virus-virus interactions at a population level.
The impact of viral co-infections on the severity of respiratory infections remains a subject of debate in the literature. Understanding the dynamics of interaction between respiratory viruses at a population level, in order to identify preferential associations or exclusions, is essential for assessing the clinical impact of co-infections.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienorte
-
-
Rhone
-
Lyon, Rhone, Frankreich, 69004
- Rekrutierung
- Infective Agents Institute, Croix rousse Hospital
-
Kontakt:
- Sophie Trouillet-Assant, PhD
- Telefonnummer: 04 72 67 87 80
- E-Mail: Sophie.trouillet-assant@chu-lyon.fr
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- - Any virological result (positive or negative) following a biological sample taken as part of routine care within the HCLs for the purpose of diagnosing a respiratory infection in a hospitalised patient.
- Patients of any age
- Samples taken during the winter periods between 2022 and 2025.
Exclusion Criteria:
- na
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Respiratory viral infections patients
Virologic results for biological samples collected as part of the diagnosis of respiratory viral infections in patients of all ages receiving routine care, regardless of their department of origin, during the winter periods from 2022 to 2025.
|
Virologic results for biological samples collected as part of the diagnosis of respiratory viral infections in patients of all ages receiving routine care, regardless of their department of origin, during the winter periods from 2022 to 2025.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Virus-virus interactions over three consecutive winters
Zeitfenster: Baseline
|
To characterize virus-virus interactions from 2022 to 2025 by assessing a co-infection exclusion score in order to identify, based on PCR results from respiratory samples collected over specific time periods (months/years), the preferred (positive) associations and exclusion (negative) relationships between respiratory viruses.
|
Baseline
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Prevalence of confirmed co-infections
Zeitfenster: Baseline
|
Frequency of virologically confirmed co-infections, defined as the proportion of participants with a positive RT-PCR test for at least two respiratory viruses.
|
Baseline
|
|
Weekly circulation of respiratory viruses
Zeitfenster: Baseline
|
Description of the weekly circulation of respiratory viruses over the study period.
|
Baseline
|
|
Weekly prevalence of respiratory viruses
Zeitfenster: Baseline
|
Proportion of respiratory viruses detected among all samples taken during the study period, regardless of the PCR result.
|
Baseline
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- 26-5170
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .